4093 Oceanside Blvd. Suite B
25 articles with Therapeutics Solutions
Therapeutic Solutions International Division of Campbell Neurosciences Files Patent on QuadraMune™ for Treatment of Major Depressive Disorder
Preclinical Data Suggests QuadraMune™ Prevents Stress-Induced Suppression of Neurogenesis More Effectively than Prozac
Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today new data from its clinical trial demonstrating an almost doubling of immune cell activity in healthy volunteers
Therapeutic Solutions International Reports Augmentation of Immunotherapy Efficacy in Breast Cancer Model Utilizing Patented NanoStilbene™ Nutraceutical Product
Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today novel data supporting utilization of the Company's NanoStilbene™ product for enhancement of cancer immunotherapy clinical trials.
Therapeutic Solutions International Reports Positive Preclinical Data on Multiple Sclerosis using NanoStilbene™
Company Continues on its Mantra of "Science Based" Nutraceutical Development in Expanding Uses of its Patented Nanotechnology based Pterostilbene
Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today the appointment of Serena Robella as Director of Sales.
Therapeutic Solutions International Announces Proof of Concept Data and Patent Filing for Neuroleukin™: The First Immune Based Suicide Prevention Biological Therapy
Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today the launch of Neuroleukin™, a personalized biological product developed to prevent suicide
Therapeutic Solutions International Files Patent on Campbell Score™: The First Quantitative Tool for Assessment of Suicidal Propensity based on Immunological Markers
Therapeutics Solutions International, Inc., (OTC Markets: TSOI), announced today filing a patent covering immunological means of quantifying risk of suicide. One embodiment of the patent is the Campbell Score™, a proprietary means of predicting risk of suicide based on ass
Therapeutic Solutions International Reports Reduction of Inflammation Associated Memory Impairment by QuadraMune™ Administration
Animal Data has Potential Implications for Ongoing COVID-19 Prevention Study Company Continues Quest to Dominate Intellectual Property Regarding COVID-19 Associated Pathologies
Therapeutic Solutions International Reports Unexpected Findings of Synergy between QuadraMune™ and Diabetes Drug Metformin in Animal Models of COVID-19 Lung Damage
New Data Suggests Nutraceutical Product May Amplify Known Beneficial Effects of AMPK Activation in Pulmonary Inflammation
Therapeutic Solutions International Reports QuadraMune™ Inhibits Inflammation Induced Blood Clotting: Possible Implication for Ongoing Covid-19 Prevention Clinical Trial?
Therapeutics Solution International, Inc., (OTC Markets: TSOI), reported today new data showing that the ingredients of QuadraMune™ suppress expression of an inflammation stimulated molecule which is known to induce coagulation of blood. Inhibition of this coagulation-promoting molecule, called Tissue Factor, was synergistic with
Therapeutic Solutions International Universal Donor Immunotherapy StemVacs™ Activates Antiviral Immune Cells While Protecting Lungs From "Cytokine Storm"
Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today new data and a patent filing showing its clinical-stage cancer immunotherapeutic product StemVacs™ appears to reduce innate immune induced inflammation in lungs while stimulating immune cells known to possess antiviral properties.
Therapeutic Solutions International Announces Intention to Use Clinical Stage NK Activating Cancer Immunotherapy for COVID-19
Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today plans to utilize its clinical-stage cancer immunotherapy StemVacs™ for treatment of COVID-19 patients. Previously
Therapeutic Solutions International Reports Reduction of Brain Inflammation/Depression Associated Biochemical Pathway Using QuadraMune™ in Animal Studies
Continued Basic Science Experiments Support New Patent Filing Covering Suppression of Indolamine 2,3 Deoxygenase Pathway by QuadraMune™
Therapeutics Solutions International, Inc., issues the following cautionary notice to the shareholders and public at large.
Therapeutic Solutions International Reports QuadraMune Reduces Myeloid Suppressor Cells in 4T1 Mouse Model of Breast Cancer
New Patent Filing Suggests Novel Mechanism of Immune Boosting Nutraceutical Can Augment Efficacy of Cancer Immunotherapy
Therapeutic Solutions International Initiates 500 Volunteer COVID-19 Prevention Clinical Trial Using QuadraMune™
Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced the initiation of a clinical trial aimed at demonstrating safety and efficacy of its immune-boosting
Therapeutic Solutions International Announces Positive Preclinical and Clinical Evaluation of Nutritional Supplement QuadraMune™, Designed to Protect Against COVID-19
Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the submission to an international medical journal the results of pre-clinical and clinical evaluation of QuadraMune™ in 32 healthy
San Diego Top Doctor Collaborates with Therapeutic Solutions International to Report QuadraMune™ Immune Boosting Data in Clinical Trial
Scientifically Formulated Nutraceutical Product Appears to Stimulate Natural Killer Cell Arm of Immune System Responsible for Suppression of Cancer and Viruses
Therapeutic Solutions International Leverages Filed and Issued Intellectual Property to Develop COVID-19 Nutraceutical Candidate: QuadraMune™
Company Intends to Initiate Clinical Trials using Novel "Multipronged" Attack on Coronavirus Pathology
Therapeutic Solutions International Enters Into Multi-million Dollar Master Sales Agreement With WCTE, Inc.
Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announces today the signing of another Master Sales Agreement with WCTE, Inc. to distribute our nutraceutical line of products.